Since ADAM17 is the subsequent step following FGFR2 activation in migration and proliferation of EC cells [25], targeting ADAM17 function in FGFR2-mutant cells may have a beneficial effect in tumor suppression. The gene discussed is FGFR2; the disease is neoplasm.